Eli Lilly & Co.
- LLY
- NYSE
- Consumer Products
- Latest 54.74
- Currency US$
- Change -0.18
- Percent Change -0.328 %
- Volume 3,952,981
- Thu May 23, 2013 4:00 PM EDT NYSE data delayed 15 minutes.
The Globe and Mail
- Open 54.67
- Previous Close 54.92
- High 55.30
- Low 54.51
- Bidx0 52.50
- Askx0 55.24
- 52-week High -- 58.405
- 52-week Low -- 39.93
- Beta 0.462
- Market Cap 61,838.68M
- EPS 3.61
- P/E 15.16
- Forward P/E 19.905
- PEG --
- Annual Dividend 1.96
- Yield 3.581
News
- Analysis: Drugmakers face more scrutiny of discordant U.S. prices
- UPDATE 1-Eli Lilly lymphoma drug fails in late-stage trial
- Eli Lilly's lymphoma drug fails in late-stage trial
- U.S. spending on medicines fell for first time in 2012
- UPDATE 2-Baxter's Alzheimer's disease drug fails in late-stage trial
- From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
- Lilly Oncology to Release New Pipeline Data at ASCO 2013
- Lilly Provides Update on CEO Dr. John Lechleiter
- Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
- Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
Financials & Calendars
- Sales $22,603,300,000
- Earnings $4,622,400,000
- Return on Equity 31.10%
- Cash Flow --
- Cash $3,936,600,000
- Current Ratio 1.62
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $32,300,100,000
- Liabilities $17,344,500,000
- Liabilities-to-Equity Ratio 1.16
Price Ratios
- Price to Sales 2.74
- Price to Book 4.13
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | Apr 24 | $1.05 | Jul 24 | $1.00 |
| Surprises | Apr 24 | 8.57% | n/a | n/a |
| Dividends | May 14 | $0.49 | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 24, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.
Officers
- John C. Lechleiter, Ph.D. Chairman of the Board; Preside
- Derica W. Rice Exec.V.P.; Global Services & C
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
LILLY CORPORATE CTR DROP CODEINDIANAPOLIS, IN
46285
Phone: 3172762000
Fax: (317)-2763492
Ideas & Discussion
Live Discussion of LLY on StockTwits